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Abstract In recent years there has been increasing concern about the rigor of laboratory
research. Here we present the protocol for a study comparing the completeness of reporting
of in vivo and in vitro research carried in Nature Publication Group journals before and
after the introduction of a change in editorial policy (the introduction of a set of guidelines
for reporting); and in similar research published in other journals in the same periods.
Keywords Risk of bias  Reporting  Methodological quality  Study design  Reporting
guidelines
Background
Few publications describing in vivo research report taking measures which might reduce
the risk of bias in their findings (Ioannidis et al. 2014; Macleod et al. 2015), and those
which do not report such measures give inflated estimates of biological effects (Crossley
et al. 2008; Hirst et al. 2014). Measures which might improve the quality of reports of
in vivo research have been proposed (Kilkenny et al. 2010; Landis et al. 2012) and while
these have been endorsed by a large number of journals there is evidence that this
endorsement has not been matched by a substantial increase in the quality of published
reports (Baker et al. 2014).
Poor replication of in vitro molecular and cellular biology studies has also been reported
(Begley and Ellis 2012; Prinz et al. 2011) and linked in part to poor descriptions of the
experimental and analytical details.
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In May 2013 Nature Journals introduced a change in editorial policy which required
authors of submissions in the life sciences to complete a checklist indicating whether or not
they had taken certain measures which might reduce the risk of bias and to report key
experimental and analytical details; and in their submission to detail where in the manu-
script these issues were addressed (Anon 2013). The purpose of this study is to assess any
impact of this change.
Study design
1:1. Aim To determine whether the implementation of a checklist for submissions has
been associated with improved reporting of measures which might reduce the risk
of bias.
1:2. Population Published articles accepted for publication in Nature journals, which
describe research in the life sciences and which were submitted after May 1st 2013
and before November 1st 2014.
1:3. Intervention Mandatory completion of a checklist at the point of manuscript
revision.
1:4. Comparator Published articles accepted for publication in Nature journals in the
months preceding May 2013, which describe research in the life sciences.
1:5. Outcome Change in proportion of published studies which report measures which
might reduce the risk of bias.
Identification of relevant manuscripts
Nature publications
One individual was specifically employed by Nature to select manuscripts based on a pre-
defined criteria for inclusion. Following this, a Nature editorial administration manager
reviewed selected manuscripts against the inclusion criteria and found that some manu-
scripts (fewer than 10 %) had been incorrectly included; they replaced these with manu-
scripts that they selected according to the inclusion algorithm. Across all participating
Nature publications (see ‘‘Appendix 1’’) that describe primary research in the life sciences
they identified papers accepted for publication with an initial submission date later than
May 1st, 2013. Beginning with the current issue (volume corresponding to year 2015), they
worked backwards in time, ensuring the submission date was after 1st May 2013, col-
lecting papers until the number of studies required was reached (‘‘Post intervention’’
group). They then used a similar process to identify papers submitted for publication before
1st May 2013, starting with the May 2013 issue and working backwards, ensuring that the
date of submission was after 1st May 2011 (‘‘pre-intervention’’ group). For each group, the
intention was that 40 papers should be selected from Nature and 20 from each of the other
titles. This would provide a total of 220 in each group and thus allow for any papers that
did not fit the study to be excluded while ensuring the study includes 200 papers per group.
The selection criteria, in addition to the dates of submission, were:
• the description of in vivo research (manuscripts that contain at least one non-human
animal experiment, including rodents, flies, worms, zebrafish etc.) or in vitro research;
316 Scientometrics (2016) 108:315–328
123
• journal of publication of Nature, Nature Neuro; Nature Immunology; Nature Cell
Biology, Nature Chemical Biology, Nature Biotechnology, Nature Methods, Nature
Medicine, or Nature Structural and Molecular Biology;
• for the post intervention group, similar proportions for country of address for
correspondence and journal.
Where no pre-intervention period match could be found with a submission date after 1st May
2011 (i.e. in the 2 years leading to the change in policy) then the non-matched post intervention
publication was excluded from analysis and a replacement post intervention publication
selected, as above, with a matching pre-intervention publication then identified, as described
above. Publications describing research involving only human subjectswere not to be included.
The published files corresponding to the publication pdfs (including the extendedmethods
section, extended data and other supplementary materials) will be used to generate pdfs for
analysis; these study pdfs will not include author names or affiliations, date, volume or page
number; or any references (to allow a blinded assessment of outcome). These study pdfs will
be presented for analysis in random order with a unique study identifier. This will be done by
the Nature editorial administration manager; Nature editors and publishers will have no role
in selecting the studymanuscripts. All studies to be includedwill be listed in anMSExcel file.
Each will then be allocated a random number between 0 and 1 using the RAND() command.
They will then be sorted according to this number and a unique identifier corresponding to
their position in this new sequencewill be allocated. These studies, with this unique identifier,
will be batch uploaded to a study computer [theEdinburghMicrosoftAccess reporting quality
scoring system (MARQSS)]. Information on group membership will be retained by the
Nature editorial administration manager. Only once data analysis is complete will the coded
group allocation (A and B) be revealed to the study team, along with coded research area,
research area and country of origin. The study team will then prepare two reports, one to be
used if group A is pre-change, and one to be used if group B is pre-change.
Sister publications
To investigate whether the changes apply only to Nature publications or whether there has
been an increase in the general scientific literature of the proportion of published studies
which report measures which might reduce the risk of bias, we will match all the Nature
publications included with a sister publication (also selected from before and after May
2013 as described above) with the following methodology:
1. Using PubMed, enter the Nature publication title.
2. Add the ‘‘related citations for PubMed’’ result to the search builder.
3. In the second line search field ‘‘Date of publication’’ for related articles in the same
calendar month (M0) and year (YYYY/MM).
4. Search.
5. In the results, start with the first result returned and establish that it was not
published in an NPG Journal (‘‘Appendix 1’’).
6. That being the case, then apply the study inclusion criteria (2.2.1), ensuring that
there is a match on the in vivo/in vitro status between Nature publications and non-
Nature publications.
7. If the manuscript fulfils 5 and 6 select it for the study and retrieve the pdf. If not
available from institutional subscriptions, seek the pdf of the paper and any
supporting materials through an interlibrary loan or from the authors.
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8. Save a pdf file comprising the main manuscript and supporting information with a
name in the form NPG\xxx[_pair_nonredact.
9. If the manuscript fails 5 or 6 repeat the search with the date of publication
extended to 1 month earlier and 1 month later (M - 1 to M ? 1).
10. Repeat steps 5 through 9 until a matching publication is found.
11. Record the difference in calendar months relative to the date of publication of the
index NPG article.
Inclusion and exclusion criteria
Manuscripts describing research in the life sciences, categorised as
1. those describing in vivo research (manuscripts that contain at least one non-human
animal experiment, including rodents, flies, worms, zebrafish etc., and where either the
exposure of interest, or the outcome, or both, are determined in whole living animals);
2. those describing exclusively vitro research (exclusively molecular and cellular biology);
3. those presenting both in vivo and in vitro experiments, as described above.
Publications describing research involving only human subjects alone will not be inclu-
ded—if there are animal studies included, the publication can still be used.
Redaction
To blind reviewers a redaction process will be carried out by a scientist in another
institution:
1. Load the pdf to Adobe acrobat professional.
2. Identify date identifying information including publication date; volume and issue
number; grant and funding information; and all references, including those which are
in-line [i.e. (Smith et al. 2015)], those which are more integrated (i.e. ‘‘In a 2015 study
by Smith and co-workers), and also in-line acknowledgements (i.e. ‘‘Reagent x kindly
donated by R. Smith’’). Additionally, any reference to years in the text was removed
(i.e. ‘‘During the 1980s…’’, ‘‘2015 census data…’’).
3. Use the redaction tool to redact these data.
4. Save the file with a name in the form NPG\xxx[_pair_redact.
5. Upload this redacted file.
Outcome assessment
Manuscripts will be scored by two independent reviewers blinded both to intervention
status (before or after the change in editorial policy) and to the scores from the other
reviewer. While the source of the publication (NPG or not, which NPG journal) will not be
redacted, this will likely be apparent to most reviewers anyway from the typeface, layout,
house style etc. Discrepancies will be resolved by a third reviewer who will be blinded to
the identity, and the scores of the previous reviewers.
We will recruit individuals experienced in the critical appraisal of published materials
(through for instance involvement with previous systematic reviews). Reviewers will
receive training using an online platform, supported by a training manual (supplementary
material). They will be presented with manuscripts to score, and their assessment
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compared with a ‘‘gold standard’’ derived following review of a set of manuscripts each
scored in house by the CAMARADES team. Once their concordance with that gold
standard is greater than 80 % for three successive manuscripts they will be considered to
have been trained to a sufficient standard.
To score a manuscript they will log on to MARQSS, and will be allocated the next
manuscript requiring to be scored for the first time. If all manuscripts held in MAQRSS at
that time have already been scored once, then the reviewer will be allocated a manuscript
for second screening. MAQRSS will ensure that reviewers do not receive for second
review a manuscript for which they performed the first review. Once manuscripts have
been scored twice MARQSS will compare those scores, item by item, and flag those
manuscripts where there is a discrepancy. These discrepancies will then be resolved by a
third, senior reviewer.
Where a manuscript describes both in vivo and in vitro research, data will be extracted
for both. Where there is more than one experimental design under each of these headings,
quality criteria must be reported for all experiments to be awarded the point, however some
checklist items will have a ‘partially’ option.
Monitoring of outcome assessment after 10 % of manuscripts have been scored and
adjudicated; we will review performance and if there are questions that are highly rep-
resented in those resulting in disagreements we will review the training materials and
amend them as appropriate.
Primary outcome measure
The proportion of publications in the intervention group describing in vivo research that
meet the Landis criteria (item numbers #2, #3, #4, #5 of ‘‘Appendix 2’’). For the purpose of
this study, meeting the criteria means that for a study in which the parameter is relevant, it
was reported as being performed or as not being performed. The evaluation principle is to
determine if someone with reasonable domain-knowledge can understand the parameters
of experimental design sufficiently to inform interpretation. These metrics will not be
applied to exploratory studies, defined for this purpose as a study where hypothesis testing
statistical analyses were not reported.
Secondary outcome measures
In vivo research
1. The change in prevalence of reporting of all of the Landis criteria (#2,3,4 and 5
together).
2. For 3 other items identified in Table 1 and for the 4 individual components of the
Landis checklist (#1,2,3,4,5,7,9), the proportion of publications in the intervention and
comparison groups considered to meet all of the relevant Nature checklist criteria.
3. For 2 other items identified inTable 1 (#6, 10), the change in the proportion of publications
meeting that criteria between the comparison group and the intervention group.
In vitro research
1. The proportion of publications in the intervention group describing in vitro research
that meet the Landis criteria (#2, #3, #4, #5 in the ‘‘Appendix 2’’).
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2. For 3 other items identified in Table 1 and for the 4 individual components of the
Landis checklist (#1,2,3,4,5,9), the proportion of publications in the intervention and
comparison groups considered to meet all of the relevant Nature checklist criteria.
3. For 2 other items identified in Table 1, the change in the proportion of publications
meeting that criteria between the comparison group and the intervention group.
The papers that contain both in vitro and in vivo research will be scored for each type of
research independently and will contribute to both of these secondary outcomes. For each
secondary outcome the denominator for calculation of proportions will total number of
papers reporting at least one in vivo or at least one in vitro experiment, respectively. We
will also evaluate whether papers reporting both in vivo and in vitro results are more or less
likely to be compliant on each secondary outcome measure.
Tertiary outcome measures
1. The proportion of publications in the intervention and comparison groups considered
to meet all of the relevant Nature checklist criteria.
2. For each of the individual components of the Nature checklist, change in the
proportion of publications meeting that criteria between the comparison group and the
intervention group.
Statistical considerations
Power calculations
The operationalized Nature checklist comprises 77 items arranged under 19 headings.
These items are very different in their form and, probably, in their relative importance. Not
all will be relevant to all studies. Further, complete compliance with the Nature guidelines,
while the desired outcome, is likely to remain uncommon; it would also be interesting to
Table 1 Detecting an editorially significant change or prevalence for specified items of the checklist
Type of studya Editorially significant
change or prevalence
Category of requirement Operationalized
checklist items
In vitro studies Animal studies
Transparency in figures and
statistical description
#1 80 % compliance 80 % compliance
Data deposition #9 80 % compliance 80 % compliance
Animals description #7 N/A 80 % compliance
‘‘Landis 4’’ #2, 3, 4, 5 15 % increment 80 % compliance
Reagents description (Ab and Cell line) #6 15 % increment 15 % increment
Code availability #10 15 % increment 15 % increment
a The unit of assessment will be considered to be the publication; while editorial intervention could occur at
any level, any impact of this would be mediated through an effect on the author, and this is therefore the
smallest unit to which an intervention might be allocated at random. Where there is more than one
experimental design under each of these headings, quality criteria must be reported for all experiments to be
awarded the point, however some checklist items will have a ‘partially’ option. However, if there are two
in vivo or in vitro experiments, one randomized non blinded one blinded non randomized, for the primary
outcome we will consider the paper to be both randomized and blinded
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observe differences in the reporting of 27 key components (items under 1,2,3,4,5 and 7) of
the checklist for animal studies, as well as relatively novel requirements (such as items
under 6 and 10). The power calculations which follow are for in vivo research; for in vitro
research they will be broadly similar.
Primary outcome (see above)
The Nature editorial team indicate that for the primary outcome they wish to know whether
compliance with the ‘‘Landis 4’’, in aggregate, reaches 80 %. Table 2 shows the upper
limits of observed compliance which might be found to be significantly lower than 80 %, at
different levels of power, for different numbers of observations, using a one-sample pro-
portion Wald test with p\ 0.05. 100 manuscripts would deliver 70 % power, 150
manuscripts would deliver 80 % power and 200 manuscripts would deliver 90 % power to
detect compliance 10 % lower than this.
Secondary outcome (in vivo research)
Table 3 shows the changes in aggregate reporting of the Landis 4 criteria identified at
different levels of power using a one sided two sample Chi squared test (STATA) (4
comparisons, p\ 0.01). Italic values are where an increase of 15 % or less is detected.
Secondary outcome (in vitro research)
Table 4 shows the upper limit of observed compliance with the Landis 4 criteria which
would be identified as being significantly less than 80 % detected with different power
using a one-sample proportion Wald test: (9 comparisons, p\ 0.0051).
Secondary outcome (see 3.2 (III))
Table 5 shows the power to detect an absolute 15 % increase in the reporting of each of #6
and #10, depending on the prevalence in the control group, using a one sided two sample
Chi squared test (STATA), with 200 manuscripts in each group (9 comparisons (with
3.2.1.2, p\ 0.0051). Italic values are where the power is[0.80.
Statistical analysis plan
We will use the Wald test to calculate the proportion (and 95 % confidence intervals) of
studies meeting the primary outcome, and for other outcomes where the proportion of
manuscripts meeting individual components of the checklist is reported (3.2.1.2). For
secondary outcomes, the 95 % confidence boundaries will be adjusted to take account of
the number of comparisons drawn (9 comparisons, p\ 0.0051, so 99.49 % CIs). We will
Table 2 Upper limits of observed compliance at different power cut-offs
Sample size (per group) 0.70 power (%) 0.80 power (%) 0.90 power (%)
100 70 68 66
150 72 71 69
200 73 72 70
250 74 73 72
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use Pearson Chi squared tests to test the significance of differences between groups for
other secondary and tertiary outcomes, again with Holm-Boneferroni adjustment of critical
p values to account for multiple testing. We will also conduct an interrupted time series
analysis using itsa in Stata, for the change in the proportion of publications meeting the
primary outcome measure with dates of submission before or after May 2013 in the
‘‘treated’’ (NPG) group compared with the ‘‘control’’ (matched) group.
We will conduct sub-group analyses in groups defined by country of origin; categori-
sation of research; and whether the study is predominantly in silico; in vitro; in vivo; or
involves human subjects.
Ethical approval
This study is a retrospective quality audit rather than a randomised trial. As such there are
no ethical concerns.
Table 3 Changes in aggregate reporting of the Landis 4 criteria identified at different levels of power
Prevalence
before (%)
Prevalence detected
(0.70 power) (%)
Prevalence detected
(0.80 power) (%)
Prevalence detected
(0.90 power) (%)
10 20 21 23
20 32 34 36
30 44 45 47
40 54 56 58
50 64 66 67
Table 4 Upper limits of observed compliance at different power cut-offs
Sample size (per group) 0.70 power (%) 0.80 power (%) 0.90 power (%)
100 65 64 61
150 68 67 65
200 70 69 67
250 71 70 69
Table 5 Power required to
detect an absolute 15 % increase
in the reporting of items #6 and
#10 of the Landis criteria items
Prevalence before (%) Prevalence after (%) Power
5 20 0.98
10 25 0.92
15 30 0.85
20 35 0.79
25 40 0.74
30 45 0.70
35 50 0.68
40 55 0.67
45 60 0.67
50 65 0.68
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Role of Nature in data analysis and data ownership
The study dataset will belong to the investigators, and all decisions relating to data analysis
and publication will be taken by the steering committee and will be independent of Nature.
Once the manuscript is written, it will be shared with NPG and they will be invited to
correct any errors of fact.
Publication policy
The entire set of derived data will be made available in a publically accessible, curated
database within 12 months of completion of the study, or upon publication of the results of
the study, whichever comes first. The study protocol will be lodged in a curated database.
Because of the potential for conflict of interest the manuscript describing this work will not
be submitted to any of the Nature journals but to a different journal.
Authorship of the main study report will include all those who have participated in the
study design, planning, data collection or analysis.
Committees
The committee structure is defined to allow separation of interests.
The study steering committee
The study steering committee is responsible for strategic decisions regarding the study; and
for data analysis, and for writing the first draft of the study report. It comprises Malcolm
Macleod (University of Edinburgh, Chief Investigator and Chair), Emily Sena (University
of Edinburgh), David Howells (School of Medicine, University of Tasmania).
The study management committee
The study management committee is responsible for ensuring the smooth running of the
study, and at the outset comprised the study steering committee along with Veronique
Kiermer (Nature). Dr Kiermer resigned from the study management committee in mid-
2015 when she left NPG, and was replaced by Dr. Sowmya Swaminathan.
Acknowledgments Funding The study is funded by a grant from the Laura and John Arnold Foundation.
Compliance with ethical standards
Conflict of interest None.
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Appendix 1: List of Nature named journals
• Nature
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• Nature Biotechnology
• Nature Cell Biology
• Nature Chemical Biology
• Nature Communications
• Nature Genetics
• Nature Immunology
• Nature Medicine
• Nature Methods
• Nature Neuroscience
• Nature Structural and Molecular Biology
Appendix 2
See Table 6.
Table 6 Operationalized checklist for Nature publication guidelines
Section title Item
number
Item
Figures and statistical
representation of data
(in vitro studies)
1.1 The legend or the main text report the exact sample size (n) for
each experimental group/condition, given as a number, not a
range?
The following items should
be found either in the
figure legends or the
methods section of the
manuscript
1.2 A description of the sample collection allowing the reader to
understand whether the samples represent technical or
biological replicates (including how many animals, litters,
cultures, etc.)?
1.3 A statement of how many times the experiment shown was
replicated in the laboratory?
1.4.1 Definitions of statistical methods and measures: If not a very
common test (such as t test, simple v2 tests, Wilcoxon and
Mann–Whitney tests, ANOVA), is the test described in the
methods section?
1.4.2 Definitions of statistical methods and measures: Are tests
reported as one-sided or two-sided?
1.4.3 Definitions of statistical methods and measures: Are there
adjustments for multiple comparisons where this is
appropriate?
1.4.4 Definitions of statistical methods and measures: Are the
statistical test results (e.g., p values, F statistic etc.) presented?
1.4.5 Definitions of statistical methods and measures: Are the
summary estimates defined as a median or average?
1.4.6 Definitions of statistical methods and measures: Are the error
bars defined as s.d., s.e.m. or c.i.?
1.5.1 Implementation of statistical methods and measures: Do the
authors show that their data meet the assumptions of the tests
(e.g., normal distribution)?
1.5.2 Implementation of statistical methods and measures: Is there an
estimate of variation within each group of data?
1.5.3 Implementation of statistical methods and measures: Is the
variance similar (difference less than twofold) between the
groups that are being statistically compared?
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Table 6 continued
Section title Item
number
Item
For in vitro study: sample
size
2 Does the manuscript describe how the sample size was chosen to
ensure adequate power to detect a pre-specified effect size?
2.1 Does the manuscript include a statement about sample size
estimate even if no statistical methods were used?
For in vitro study: exclusions 3 Does the manuscript describe if samples or animals were
excluded from the analysis?
3.1 Are exclusion criteria defined?
3.2 Is it clear that the criteria were pre-established?
For in vitro study:
randomization
4 Does the manuscript describe which method of randomization
was used to determine how samples/animals were allocated to
experimental groups?
4.1 Does the manuscript describe include a statement about
randomization even if no randomization was used?
For in vitro study: blinding 5 Does the manuscript describe whether the investigator was
blinded to the group allocation during the experiment and/or
when assessing the outcome?
5.1 Does the manuscript include a statement about blinding even if
no blinding was done?
For in vitro study: reagents 6.1 Has every antibody used in this manuscript been profiled for use
in the system under study, by either citation, catalog number,
clone number or validation profile?
6.2.1 Was the source of cell lines provided?
6.2.2 Do the authors report whether the lines used have been
authenticated recently (e.g., by STR profiling: within 1 year of
use)?
6.2.3 Do the authors report whether the lines used have been tested for
mycoplasma contamination recently (within 6 months of use)?
For in vivo study: figures and
statistical representation of
data: for each figure (and
each panel, where relevant),
does the legend or the main
text report
1.1 The legend or the main text report the exact sample size (n) for
each experimental group/condition, given as a number, not a
range?
1.2 A description of the sample collection allowing the reader to
understand whether the samples represent technical or
biological replicates (including how many animals, litters,
cultures, etc.)?
1.3 A statement of how many times the experiment shown was
replicated in the laboratory?
1.4.1 Definitions of statistical methods and measures: If not a very
common test (such as t test, simple v2 tests, Wilcoxon and
Mann–Whitney tests, ANOVA), is the test described in the
methods section?
1.4.2 Definitions of statistical methods and measures: Where
appropriate are tests reported as one-sided or two-sided?
1.4.3 Definitions of statistical methods and measures: Are there
adjustments for multiple comparisons where this is
appropriate?
1.4.4 Definitions of statistical methods and measures: Are the
statistical test results (e.g., p values, F statistic etc.) presented?
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Table 6 continued
Section title Item
number
Item
1.4.5 Definitions of statistical methods and measures: Are the
summary estimates defined as a median or average?
1.4.6 Definitions of statistical methods and measures: Are the error
bars defined as s.d., s.e.m. or c.i.?
1.5.1 Implementation of statistical methods and measures: Do the
authors show that their data meet the assumptions of the tests
(e.g., normal distribution)?
1.5.2 Implementation of statistical methods and measures: Is there an
estimate of variation within each experimental group of data
(e.g. Control vs Intervention group)?
1.5.3 Implementation of statistical methods and measures: Is the
variance similar (difference less than twofold) between the
groups that are being statistically compared?
For in vivo study: sample size 2 Does the manuscript describe how the sample size was chosen to
ensure adequate power to detect a pre-specified effect size?
2.1 Does the manuscript include a statement about sample size
estimate even if no statistical methods were used?
For in vivo study: exclusions 3 Does the manuscript describe if samples or animals were
excluded from the analysis?
3.1 Are inclusion and exclusion criteria defined?
3.2 Is it clear that the criteria were pre-established?
For in vivo study:
randomization
4 Does the manuscript describe which method of randomization
was used to determine how samples/animals were allocated to
experimental groups?
4.1 Does the manuscript describe include a statement about
randomization even if no randomization was used?
For in vivo study: blinding 5 Does the manuscript describe whether the investigator was
blinded to the group allocation during the experiment and/or
when assessing the outcome?
5.1 Does the manuscript include a statement about blinding even if
no blinding was done?
For in vivo study: reagents 6.1 Has every antibody used in this manuscript been profiled for use
in the system under study, by either citation, catalog number,
clone number or validation profile?
For in vivo study: non-human
animal studies
7.1.1 Does the study report the Species?
7.1.2 Does the study report the Strain?
7.1.3 Does the study report the Sex?
7.1.4 Does the study report the age or weight (exact numbers required
not ranges)?
7.2.1 Does the study include a statement of compliance with ethical
regulations?
7.2.2 Does the study include the committee(s) approving the
experiments?
For manuscript that include
human studies
8.1 Does the manuscript identify the committee(s) approving the
study protocol?
8.2 Does the manuscript include a statement confirming that
informed consent was obtained from all subjects?
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Table 6 continued
Section title Item
number
Item
8.3 For publication of patient photos, does the study include a
statement confirming that consent to publish was obtained?
8.4 Does the study report the clinical trial registration number (at
ClinicalTrials.gov or equivalent)?
8.5 For phase II and III randomized controlled trials, does the
supplementary material include a CONSORT checklist?
8.6 For tumor marker prognostic studies, does the supplementary
material include a REMARK checklist?
Data deposition 9.1 For studies describing Protein, DNA and RNA sequences, is an
accession code for deposited data in a public repository
provided?
9.1.1 Does that accession code give access to the data?
9.2 For studies describing Macromolecular structures, is an
accession code for deposited data in a public repository
provided?
9.2.1 Does that accession code give access to the data?
9.3 For studies describing Crystallographic data for small molecules,
is an accession code for deposited data in a public repository
provided?
9.3.1 Does that accession code give access to the data?
9.4 For studies describing microarray data, is an accession code for
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